Five of America's biggest drug companies got letters from Congress today. Read those letters carefully.

Some days the most important story is also the quietest one. Today it arrived in five envelopes.

The drug companies that thought China was just a market

A bipartisan group of lawmakers led by Representative John Moolenaar, chair of the House Select Committee on China, opened national security investigations today into five of America's largest pharmaceutical companies — Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb — over their clinical trial operations in China. The companies have until July 17 to provide details on data protection standards and oversight at their Chinese trial sites, particularly in the Xinjiang region and at hospitals affiliated with China's military. Shares of all five fell nearly 2% in early trading. AccountableHQ

Here's the read that doesn't come from clicking the Reuters link. The letters explicitly say there is no evidence of wrongdoing. Congress is not accusing anyone of anything yet. What Congress is doing is something more consequential for the long run: it is establishing, in writing, that clinical trials at Chinese military hospitals are a national security issue, not just a regulatory compliance question. That framing shift matters enormously. Moolenaar is also sponsoring the Biotech Investment National Security Act, which would add biotech to the list of technologies subject to strict outbound investment review, and a separate Biosecure Act signed into law last year already restricts federal agencies from doing business with non-US biotech companies. PBS

The legislative architecture is being built piece by piece. Today's letters are not the end of a process; they are the beginning of one. Any pharma company with meaningful China clinical trial exposure just had its risk profile quietly repriced by a bipartisan committee on Tuesday morning.

The best quarter in six years, and almost nobody said it out loud

Today is the final day of what will likely turn out to be the best quarter for the S&P 500 and Nasdaq in six years, despite the Iran war. The Dow is set for its best quarter since 2022. Stocks opened little-changed Tuesday as investors waited on jobs data. Manatt, Phelps & Phillips, LLP

That contrast, the best quarter in six years, during an active war in the Persian Gulf, is the intelligence brief version of a blinking light. Markets are not pricing in the Iran conflict as an existential economic event. They are pricing it as a managed disruption with a negotiating track. The moment that assumption breaks, and it could break on a single Hormuz headline, the repricing will be sharp precisely because it hasn't been priced in gradually.

Today's JOLTS data gave the market something to work with: job openings were expected to show a slight drop to 7.3 million, but the labor market has shown recent signs of strength, with openings hitting a nearly two-year high in April and the ratio of openings to unemployed workers back above one. A labor market this tight gives the Fed permission to stay restrictive. That's not bad news dressed up as good news. It's a genuinely complicated signal that Thursday's NFP report will either clarify or complicate further. Manatt, Phelps & Phillips, LLP

A drone company just told you more about defense spending than the Pentagon's budget did

AeroVironment gained more than 30% in early trading today after a blockbuster earnings report, with CEO Wahid Nawabi telling CNBC that the conflicts in Ukraine and Iran had fundamentally changed the nature of war. Manatt, Phelps & Phillips, LLP

AeroVironment makes small tactical drones. Not the Predator-scale systems defense contractors have sold for decades. The kind soldiers carry in backpacks and launch by hand. A 30% single-session gain on an earnings beat is remarkable. But the CEO's comment is the actual signal: the conflicts in Ukraine and Iran changed the fundamentals of war. That's not a marketing line. That's a structural observation about where defense procurement is heading, away from expensive, low-volume platforms and toward cheap, high-volume, expendable systems that can be manufactured at scale. The companies positioned for that shift are not always the ones on the traditional defense contractor list.

Yesterday's thread, one day later

Iran talks remain in technical limbo. A Pakistani source said talks between Washington and Tehran had been put on hold, but that US, Iranian, Pakistani and Qatari representatives were all in Switzerland waiting to restart discussions when instructed. A senior Trump administration official said nothing had been cancelled and that technical talks were on track. Two official positions, same situation, neither confirming a breakthrough. The procedural detail worth watching: both sides are still in the room, just not talking yet. That is different from walking away, and the market is reading it that way, oil held relatively steady rather than spiking on the "on hold" headline. Center for Strategic and International Studies

The thread underneath today

A pharma investigation framed as national security, a record quarter nobody is celebrating too loudly, a drone company redefining what defense spending looks like, and a peace process that is technically paused but physically still in the building. What connects them is a single condition: every major actor today is managing the gap between what they say publicly and what they are actually doing. Pharma companies are running trials at military hospitals while saying they follow global guidelines. Markets posting record quarters while a war runs in the background. Iran in Switzerland waiting to talk while officially saying talks are on hold.

That gap, between the statement and the reality, is where Capital to Capitol lives.

What to watch tomorrow: Thursday's NFP print is now the single most market-moving event of the week. And watch whether any of the five pharma companies respond to Congress before July 17, because the ones that respond early are telling you something about how exposed they actually feel.

Capital to Capitol publishes every evening. Subscribe free below and today's brief lands in your inbox by 9 PM.